



King's Research Portal

DOI:

[10.1111/bcp.13929](https://doi.org/10.1111/bcp.13929)

Document Version

Peer reviewed version

[Link to publication record in King's Research Portal](#)

Citation for published version (APA):

Webb, A. J., & Minuz, P. (2019). Spotlight Commentary: What's new with the old drug aspirin in older adults? *British Journal of Clinical Pharmacology*, 85(7), 1391-1392. <https://doi.org/10.1111/bcp.13929>

Citing this paper

Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections.

General rights

Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the Research Portal

Take down policy

If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.

What's *new* with the *old* drug Aspirin in *older* adults?

Andrew James Webb and Pietro Minuz

The benefit-to-harm balance of aspirin has been further questioned recently. What should prescribers do? The European Society of Cardiology (ESC) Guidelines, most recently updated in 2016 [1], do not recommend the use of aspirin for primary prevention (patients without prior major cardio- or cerebrovascular event) due to the high risk of bleeding. This position is now further supported by the results of the Aspirin in Reducing Events in the Elderly ASPREE trial [2]. Aspirin significantly increased the risk of major haemorrhage without lowering the risk of cardiovascular disease, compared to placebo.

In the BJCP/Journal, Ardoino and colleagues found high rates of prescription of antiplatelet drugs (with aspirin being the most frequently chosen): almost half (43.6%, 95% CI 41.5-45.7) of 959 patients aged 65 or over in Italian and Spanish internal medicine and geriatric wards in 2012 and 2014 (as part of the REPOSI ((REgistro POLiterapie SIMI)) register) [3]. Moreover, just over half (52.1%) were prescribed aspirin inappropriately. In most cases, this was over-prescription (74.2%) in patients with a Systematic Coronary Risk Evaluation Project (SCORE) <10%. Against this over-prescription of aspirin for primary prevention, Ardoino et al., also found substantial under-prescription (30.6%) of antiplatelet agents in patients who were secondary prevention [3].

Ardoino et al., also found further inappropriate use of antiplatelets in patients with atrial fibrillation (AF) - who should have been anticoagulated.

The risks of major bleeding and stroke with aspirin and anticoagulants used for AF has been reported in the Journal by Gieling et al., who studied their use in 31,497 patients with AF (2008-2014) using the UK Clinical Practice Research Datalink [4]. Aspirin was found to have a similar bleeding risk to vitamin K antagonists (VKAs) but that VKAs were more effective than aspirin (hazard ratio (HR) 2.18, [95% confidence interval (95%CI) 1.83-2.59] in the prevention of ischaemic stroke. Whilst Nonvitamin K antagonist oral anticoagulants (NOACs) were similarly effective as VKA in preventing ischaemic stroke (HR 1.22, 95% CI 0.67-2.19), they were associated with double the risk of major bleeding – mainly gastrointestinal [2.07 (95%CI 1.27-3.38)], a risk restricted to women (HR 3.14, 95% CI 1.76-5.60). However, caution should be applied as this was a retrospective cohort study, albeit in a large population.

Despite this poor benefit-to-harm balance of aspirin, Parekh et al., found that anti-platelets agents were only 13th on a list of medications associated with medication-related harms (MRH) following hospital discharge in 1280 older adults [5]. Aspirin was behind opiates, antibiotics, benzodiazepines, diuretics and antihypertensives. The overall incidence of MRH-associated hospital readmission was ~8% (78 per 1000 discharges), at an estimated cost to the National Health Service of £396 million annually, over 60% of which (£243 million) was considered to be potentially preventable [5].

Therefore, whilst prescribers should remember the need for antiplatelets in secondary prevention, they should reconsider the use of aspirin for primary prevention and focus more on good control of the other risk factors: blood pressure and cholesterol (the latter mainly via use of statins). Perhaps the current success of these other interventions now leaves little room for benefit from aspirin in primary prevention?

References

1. Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, Cooney MT, Corra U, Cosyns B, Deaton C, Graham I, Hall MS, Hobbs FDR, Lochen ML, Lollgen H, Marques-Vidal P, Perk J, Prescott E, Redon J, Richter DJ, Sattar N, Smulders Y, Tiberi M, van der Worp HB, van Dis I, Verschuren WMM, Binno S, Group ESCSD. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). *Eur Heart J* 2016; 37: 2315-81.
2. McNeil JJ, Nelson MR, Woods RL, Lockery JE, Wolfe R, Reid CM, Kirpach B, Shah RC, Ives DG, Storey E, Ryan J, Tonkin AM, Newman AB, Williamson JD, Margolis KL, Ernst ME, Abhayaratna WP, Stocks N, Fitzgerald SM, Orchard SG, Trevaks RE, Beilin LJ, Donnan GA, Gibbs P, Johnston CI, Radziszewska B, Grimm R, Murray AM, Group AI. Effect of Aspirin on All-Cause Mortality in the Healthy Elderly. *The New England journal of medicine* 2018; 379: 1519-28.
3. Ardoino I, Rossio R, Di Blanca D, Nobili A, Pasina L, Mannucci PM, Peyvandi F, Franchi C, Investigators R. Appropriateness of antiplatelet therapy for primary and secondary cardio- and cerebrovascular prevention in acutely hospitalized older people. *British journal of clinical pharmacology* 2017; 83: 2528-40.
4. Gieling EM, van den Ham HA, van Onzenoort H, Bos J, Kramers C, de Boer A, de Vries F, Burden AM. Risk of major bleeding and stroke associated with the use of vitamin K antagonists, nonvitamin K antagonist oral anticoagulants and aspirin in patients with atrial fibrillation: a cohort study. *British journal of clinical pharmacology* 2017; 83: 1844-59.
5. Parekh N, Ali K, Stevenson JM, Davies JG, Schiff R, Van der Cammen T, Harchowal J, Raftery J, Rajkumar C, group Ps. Incidence and cost of medication harm in older adults following hospital discharge: a multicentre prospective study in the UK. *British journal of clinical pharmacology* 2018; 84: 1789-97.